Forma Therapeutics Holdings, Inc.

2022 Q1 Form 10-K Financial Statement

#000095017022002527 Filed on March 01, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q4 2021

Balance Sheet

Concept 2022 Q1 2021 Q4 2021
SHORT-TERM ASSETS
Cash & Short-Term Investments $421.4M $464.2M $464.2M
YoY Change -23.49% -26.67% -26.67%
Cash & Equivalents $74.42M $77.42M $77.42M
Short-Term Investments $346.9M $386.8M $386.8M
Other Short-Term Assets $11.42M $9.108M $9.108M
YoY Change 40.96% 586.36% 49.31%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $446.5M $486.4M $486.4M
YoY Change -22.19% -25.68% -25.67%
LONG-TERM ASSETS
Property, Plant & Equipment $13.55M $13.93M $36.00M
YoY Change 854.23% 816.25% 2300.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $19.99M $26.05M $26.05M
YoY Change -62.29% 108.38% 108.38%
Other Assets $12.82M $12.61M $12.61M
YoY Change -14.55% 1.14% 0.9%
Total Long-Term Assets $67.97M $74.66M $74.66M
YoY Change -10.91% 181.48% 180.68%
TOTAL ASSETS
Total Short-Term Assets $446.5M $486.4M $486.4M
Total Long-Term Assets $67.97M $74.66M $74.66M
Total Assets $514.5M $561.1M $561.1M
YoY Change -20.87% -17.61% -17.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.044M $4.145M $4.145M
YoY Change -29.52% -3.49% -3.6%
Accrued Expenses $19.09M $25.75M $29.41M
YoY Change -28.51% -5.0% 12.68%
Deferred Revenue $0.00
YoY Change -100.0%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $26.34M $35.09M $35.09M
YoY Change -7.91% 10.69% 10.69%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $26.97M $27.62M $27.62M
YoY Change 418.6% 2661.7% 2661.7%
Total Long-Term Liabilities $26.97M $27.62M $27.62M
YoY Change 418.6% 2661.7% 2661.7%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.34M $35.09M $35.09M
Total Long-Term Liabilities $26.97M $27.62M $27.62M
Total Liabilities $53.30M $62.71M $62.71M
YoY Change 57.7% 91.6% 91.76%
SHAREHOLDERS EQUITY
Retained Earnings -$274.5M -$230.4M
YoY Change 301.28%
Common Stock $735.7M $728.7M
YoY Change 3.27%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $461.2M $498.4M $498.4M
YoY Change
Total Liabilities & Shareholders Equity $514.5M $561.1M $561.1M
YoY Change -20.87% -17.61% -17.61%

Cashflow Statement

Concept 2022 Q1 2021 Q4 2021

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Assets Current
AssetsCurrent
654447000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13927000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1520000
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
11988000
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
CY2021 dei City Area Code
CityAreaCode
617
CY2021 dei Local Phone Number
LocalPhoneNumber
679-1970
CY2021 dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
CY2021 dei Trading Symbol
TradingSymbol
FMTX
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
350365000
CY2020Q4 fmtx Cost For Guarantees And Indemnities
CostForGuaranteesAndIndemnities
0
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001538927
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 fmtx Cost For Guarantees And Indemnities
CostForGuaranteesAndIndemnities
0
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-39333
CY2021 dei Entity Registrant Name
EntityRegistrantName
Forma Therapeutics Holdings, Inc.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
37-1657129
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
300 North Beacon Street
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 501
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
1179268114
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
47472985
CY2021 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2021 dei Auditor Location
AuditorLocation
Boston, Massachusetts
CY2021 dei Auditor Firm
AuditorFirmId
42
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
77421000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
282689000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
386805000
CY2020Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
15273000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10187000
CY2021Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
26047000
CY2020Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
12534000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22074000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6120000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
486401000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12612000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12470000
CY2021Q4 us-gaap Assets
Assets
561061000
CY2020Q4 us-gaap Assets
Assets
680971000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4145000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4295000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25748000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
27104000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5125000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2021Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
70000
CY2020Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
301000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
35088000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
31700000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
27617000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2021Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
0
CY2020Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1027000
CY2021Q4 us-gaap Liabilities
Liabilities
62705000
CY2020Q4 us-gaap Liabilities
Liabilities
32727000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47411356
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47300231
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47398238
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47248685
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
47000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
47000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
728683000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
705607000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-230374000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-57410000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
498356000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
648244000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
561061000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
680971000
CY2021 us-gaap Revenues
Revenues
0
CY2020 us-gaap Revenues
Revenues
0
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
125661000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
93367000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
48325000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
30782000
CY2021 us-gaap Restructuring Charges
RestructuringCharges
0
CY2020 us-gaap Restructuring Charges
RestructuringCharges
63000
CY2021 us-gaap Operating Expenses
OperatingExpenses
173986000
CY2020 us-gaap Operating Expenses
OperatingExpenses
124212000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-173986000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-124212000
CY2021 fmtx Gain On Hit Discovery Divestiture
GainOnHitDiscoveryDivestiture
0
CY2020 fmtx Gain On Hit Discovery Divestiture
GainOnHitDiscoveryDivestiture
23312000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
1054000
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
3428000
CY2021 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
122000
CY2020 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
-2661000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1176000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
24079000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-172810000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-100133000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
154000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
29719000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-172964000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-70414000
CY2021 fmtx Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-172964000
CY2020 fmtx Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-74150000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.65
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.22
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47347343
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23056975
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
18246000
CY2020 fmtx Accretion Of Cumulative Dividends On Redeemable Convertible Preferred Stock
AccretionOfCumulativeDividendsOnRedeemableConvertiblePreferredStock
-3736000
CY2020 fmtx Stock Issued During Period Value Exercise Of Warrants To Purchase Common Stock
StockIssuedDuringPeriodValueExerciseOfWarrantsToPurchaseCommonStock
12000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
378000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6959000
CY2020 fmtx Conversion Of Temporary Equity To Common Stock Value
ConversionOfTemporaryEquityToCommonStockValue
141867000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
293338000
CY2020 fmtx Exercise Of Warrants To Purchase Common Stock Net
ExerciseOfWarrantsToPurchaseCommonStockNet
2961000
CY2020 fmtx Issuance Of Common Stock From Follow On Public Offering Net Of Costs
IssuanceOfCommonStockFromFollowOnPublicOfferingNetOfCosts
258633000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-70414000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
648244000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
513000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22563000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-172964000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
498356000
CY2021 us-gaap Profit Loss
ProfitLoss
-172964000
CY2020 us-gaap Profit Loss
ProfitLoss
-70414000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1569000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1276000
CY2021 fmtx Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
1025000
CY2021 fmtx Gain Loss On Lease Modification
GainLossOnLeaseModification
287000
CY2021 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
22563000
CY2020 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
6959000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2597000
CY2021 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-1243000
CY2020 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
559000
CY2020 fmtx Gain On Hit Discovery Divestiture
GainOnHitDiscoveryDivestiture
23312000
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-219000
CY2020 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-59000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-227000
CY2021 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-3285000
CY2020 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
14681000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4432000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3872000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-173000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
933000
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-457000
CY2020 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
6755000
CY2021 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
-231000
CY2020 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
301000
CY2020 fmtx Increase Decrease In Deferred Rent Noncurrent
IncreaseDecreaseInDeferredRentNoncurrent
-399000
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1147000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-149787000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-95418000
CY2021 us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
578501000
CY2020 us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
479633000
CY2021 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
527305000
CY2020 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
116175000
CY2020 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
46000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4179000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
249000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-55375000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-345821000
CY2020 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
293338000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
259133000
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
12000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
513000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
378000
CY2021 us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
972000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-459000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-205621000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
111363000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
173796000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
79538000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
552602000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
285159000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
285159000
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
45.25
CY2021Q4 fmtx Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
490300000
CY2020Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
795000
CY2020Q4 fmtx Gross Proceeds From Follow On Public Offering
GrossProceedsFromFollowOnPublicOffering
275800000
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
334000
CY2020 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
187000
CY2021 fmtx Right Of Use Asset Recognized Upon Adoption Of Operating Lease
RightOfUseAssetRecognizedUponAdoptionOfOperatingLease
7478000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
21213000
CY2020 fmtx Accretion Of Preferred Return Cumulative Dividends And Issuance Costs On Preferred Securities
AccretionOfPreferredReturnCumulativeDividendsAndIssuanceCostsOnPreferredSecurities
3736000
CY2021 fmtx Public Offering Costs Included In Accounts Payable And Accrued Expenses
PublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
23000
CY2020 fmtx Public Offering Costs Included In Accounts Payable And Accrued Expenses
PublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
500000
CY2020 fmtx Net Exercise Of Warrants To Purchase Common Stock
NetExerciseOfWarrantsToPurchaseCommonStock
2961000
CY2020Q4 fmtx Equity Consideration
EquityConsideration
10000000
CY2020 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
3000
CY2020 fmtx Conversion Of Redeemable Convertible And Convertible Preferred Stock Into Common Stock
ConversionOfRedeemableConvertibleAndConvertiblePreferredStockIntoCommonStock
142252000
CY2021 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
15964704
CY2021Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
20.00
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q2 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
160000000
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 fmtx Proceeds From Follow On Offering After Deducting Expenses
ProceedsFromFollowOnOfferingAfterDeductingExpenses
258600000
CY2021Q3 fmtx Aggregate Amount Of Issuance And Offering Cost
AggregateAmountOfIssuanceAndOfferingCost
200000000.0
CY2021Q3 fmtx Sales Agent Cash Commissions
SalesAgentCashCommissions
0.030
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, equity-based compensation, research and development expenses and related accruals, leases, and income taxes. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company’s estimates.</span>
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
285159000
CY2021 fmtx Short Term Highly Liquid Investments With Original Maturities
ShortTermHighlyLiquidInvestmentsWithOriginalMaturities
90 days or less
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
77421000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
282689000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
2117000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
2470000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
79538000
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Concentration of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Financial instruments which potentially expose the Company to concentrations of credit risk include cash, cash equivalents, restricted cash and marketable securities. The Company maintains its cash, cash equivalents, restricted cash and marketable securities with accredited financial institutions and,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">consequently, the Company does not believe it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Concentration of credit risk with respect to receivables is limited to certain customers to which the Company makes substantial sales. Customers are granted credit on an unsecured basis. To mitigate risk, the Company routinely assesses the financial strength of its customers which are primarily large pharmaceutical companies. The Company’s policy is to maintain allowances for estimated losses associated with the inability of its customers to make required payments. The Company provides an allowance for doubtful accounts based on known accounts receivable balances that are determined to be uncollectible, historical experience and other currently available evidence. The Company’s senior management reviews accounts receivable balances on a periodic basis to determine if any receivables may be potentially uncollectable. An amount is written off against the allowance after all attempts have failed to collect the receivable. Based on management’s review, </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> allowances for doubtful accounts were recorded as of and for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">December 31, 2021 and 2020. The Company had no accounts receivable balances as of and for the years ended December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2021 fmtx Payments For Sales And Services Due Period
PaymentsForSalesAndServicesDuePeriod
P30D
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.04
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.04
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
8900000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7500000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
27104000
CY2020Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1027000
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
487643000
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
625392000
CY2021Q4 fmtx Manufacturing And Clinical Prepaid Expenses
ManufacturingAndClinicalPrepaidExpenses
5559000
CY2020Q4 fmtx Manufacturing And Clinical Prepaid Expenses
ManufacturingAndClinicalPrepaidExpenses
3068000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
3549000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1725000
CY2021Q4 us-gaap Other Receivables
OtherReceivables
1079000
CY2020Q4 us-gaap Other Receivables
OtherReceivables
1327000
CY2020Q3 fmtx Accretion Of Cumulative Dividends Redeemable Convertible Preferred Shares
AccretionOfCumulativeDividendsRedeemableConvertiblePreferredShares
46.37
CY2021Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
412852000
CY2021Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
38000
CY2021Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
204000
CY2021Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
412686000
CY2020Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
362899000
CY2020Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
38000
CY2020Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
25000
CY2020Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
362912000
CY2021Q4 fmtx Aggregate Fair Value Unrealized Loss Position
AggregateFairValueUnrealizedLossPosition
219300000
CY2020Q4 fmtx Aggregate Fair Value Unrealized Loss Position
AggregateFairValueUnrealizedLossPosition
93700000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
23166000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
2193000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10187000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6120000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18696000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13065000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4769000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11545000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13927000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1520000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1600000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1300000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
1983000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
752000
CY2021 us-gaap Lease Cost
LeaseCost
2735000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5321000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5427000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4676000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
4816000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
4920000
CY2021Q4 fmtx Other Research And Development Related Accruals
OtherResearchAndDevelopmentRelatedAccruals
3804000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
48326000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
15584000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
32742000
CY2021 fmtx Operating Lease Weighted Average Incremental Borrowing Rate Percent
OperatingLeaseWeightedAverageIncrementalBorrowingRatePercent
0.087
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y1M6D
CY2020 fmtx Rent Expense Under Lease
RentExpenseUnderLease
2300000
CY2020Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
1400000
CY2021Q4 fmtx Manufacturing And Clinical Accruals
ManufacturingAndClinicalAccruals
11001000
CY2020Q4 fmtx Manufacturing And Clinical Accruals
ManufacturingAndClinicalAccruals
16847000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8508000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6834000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
971000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1008000
CY2020Q4 fmtx Other Research And Development Related Accruals
OtherResearchAndDevelopmentRelatedAccruals
1443000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1464000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
972000
CY2021Q4 fmtx Accrued Expenses And Other Liabilities Current Net
AccruedExpensesAndOtherLiabilitiesCurrentNet
25748000
CY2020Q4 fmtx Accrued Expenses And Other Liabilities Current Net
AccruedExpensesAndOtherLiabilitiesCurrentNet
27104000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4941537
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.62
CY2019Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.40
CY2019Q1 us-gaap Restructuring Charges
RestructuringCharges
5400000
CY2021 us-gaap Restructuring And Related Activities Description
RestructuringAndRelatedActivitiesDescription
There were no restructuring activities during the twelve months ended December 31, 2021.
CY2019Q4 us-gaap Restructuring Reserve
RestructuringReserve
325000
CY2020 us-gaap Restructuring Charges
RestructuringCharges
63000
CY2020 us-gaap Severance Costs1
SeveranceCosts1
-388000
CY2020Q4 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2020Q2 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
20349223
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Convertible Preferred Stock Shares Reserved For Future Issuance
ConvertiblePreferredStockSharesReservedForFutureIssuance
10168654
CY2020Q4 us-gaap Convertible Preferred Stock Shares Reserved For Future Issuance
ConvertiblePreferredStockSharesReservedForFutureIssuance
7920499
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y1M6D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
130802000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1410920
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
34.30
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
102818
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.15
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
307070
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
21.29
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5942569
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.12
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
33891000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2457025
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.22
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y7M6D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
18426000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5942569
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
14.12
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y1M6D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
33891000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0097
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0109
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.779
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.748
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2021 fmtx Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price1
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice1
34.30
CY2020 fmtx Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price1
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice1
10.60
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
52000
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
29000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22563000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6959000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22563000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6959000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
200000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
29700000
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
102000
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-29748000
CY2021 fmtx Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.000
CY2020 fmtx Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.005
CY2021 fmtx Effective Income Tax Rate Reconciliation At Cares Act Tax Rate Differential
EffectiveIncomeTaxRateReconciliationAtCARESActTaxRateDifferential
0.001
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
0
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1802000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
2138000
CY2021 fmtx Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate Net
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateNet
-0.210
CY2020 fmtx Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate Net
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateNet
-0.210
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
37107000
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.048
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.049
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.011
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.010
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.006
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.000
CY2021Q4 fmtx Deferred Tax Assets Capitalized Expenses
DeferredTaxAssetsCapitalizedExpenses
2976000
CY2020Q4 fmtx Deferred Tax Assets Capitalized Expenses
DeferredTaxAssetsCapitalizedExpenses
3202000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3660000
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
154000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
29719000
CY2020 fmtx Effective Income Tax Rate Reconciliation At Cares Act Tax Rate Differential
EffectiveIncomeTaxRateReconciliationAtCARESActTaxRateDifferential
-0.144
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.284
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.133
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.001
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.297
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
49244000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
11036000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
44385000
CY2021Q4 us-gaap Lease Deposit Liability
LeaseDepositLiability
6064000
CY2020Q4 us-gaap Lease Deposit Liability
LeaseDepositLiability
0
CY2021Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
256000
CY2020Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
41000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
108387000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
53524000
CY2021Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
5768000
CY2020Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
0
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
102619000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
53524000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
0
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
0
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
102600000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
53500000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
49100000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2020 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1239000
CY2021 fmtx Contract With Customer Liability Current Additions
ContractWithCustomerLiabilityCurrentAdditions
0
CY2021 fmtx Contract With Customer Liability Current Deductions
ContractWithCustomerLiabilityCurrentDeductions
1239000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0
CY2021 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
0
CY2020 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
0
CY2021Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2020Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2021 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
1
CY2021 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.06
CY2021 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
1400000
CY2020 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
1100000
CY2021 us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
17500000
CY2021Q4 fmtx Prepaid Of Reimbursement Expense
PrepaidOfReimbursementExpense
500000
CY2021Q4 fmtx Equity Consideration
EquityConsideration
10000000.0
CY2021Q4 us-gaap Disposal Group Including Discontinued Operation Deferred Revenue
DisposalGroupIncludingDiscontinuedOperationDeferredRevenue
1239000
CY2021Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
1398000
CY2021Q4 us-gaap Disposal Group Deferred Gain On Disposal
DisposalGroupDeferredGainOnDisposal
2242000
CY2021Q4 fmtx Cash Due At Closing
CashDueAtClosing
2961000
CY2021Q4 fmtx Installment Receivable
InstallmentReceivable
12593000
CY2021Q4 fmtx Equity Consideration
EquityConsideration
10000000
CY2021Q4 fmtx Fair Value Of Consideration
FairValueOfConsideration
25554000
CY2021Q4 us-gaap Disposal Group Including Discontinued Operation Prepaid And Other Assets Current
DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
1117000
CY2021Q4 us-gaap Disposal Group Including Discontinued Operation Property Plant And Equipment Noncurrent
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent
2398000
CY2021Q4 us-gaap Disposal Group Including Discontinued Operation Other Noncurrent Assets
DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets
125000
CY2021Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation
AssetsOfDisposalGroupIncludingDiscontinuedOperation
3640000
CY2021Q4 us-gaap Disposal Group Including Discontinued Operation Accounts Payable
DisposalGroupIncludingDiscontinuedOperationAccountsPayable
159000

Files In Submission

Name View Source Status
0000950170-22-002527-index-headers.html Edgar Link pending
0000950170-22-002527-index.html Edgar Link pending
0000950170-22-002527.txt Edgar Link pending
0000950170-22-002527-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
fmtx-20211231.htm Edgar Link pending
fmtx-20211231.xsd Edgar Link pending
fmtx-20211231_cal.xml Edgar Link unprocessable
fmtx-20211231_def.xml Edgar Link unprocessable
fmtx-20211231_htm.xml Edgar Link completed
fmtx-20211231_lab.xml Edgar Link unprocessable
fmtx-20211231_pre.xml Edgar Link unprocessable
fmtx-ex10_13.htm Edgar Link pending
fmtx-ex10_3.htm Edgar Link pending
fmtx-ex23_1.htm Edgar Link pending
fmtx-ex31_1.htm Edgar Link pending
fmtx-ex31_2.htm Edgar Link pending
fmtx-ex32_1.htm Edgar Link pending
fmtx-ex32_2.htm Edgar Link pending
img103760062_0.jpg Edgar Link pending
img103760062_1.jpg Edgar Link pending
img103760062_2.jpg Edgar Link pending
img103760062_3.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending